Navigation Links
Women & Infants studying therapies to relieve urinary urge incontinence
Date:2/29/2012

Overactive bladder, or the sudden urge to urinate, affects the quality of life of many women. Studies have shown that not all women respond to or can tolerate oral medications and may benefit from other therapies.

Women & Infants Hospital of Rhode Island is conducting a study to compare the effect of two therapies in women who have bothersome urinary urge incontinence after trying other treatments. Patients are currently being enrolled in the ROSETTA Study Reftractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment. The ROSETTA Study is part of the national Pelvic Floor Disorders Network which is funded by the National Institute of Child Health and Development and the Office of Research on Women's Health.

Principal investigator at Women & Infants is Deborah Myers, MD, director of the Division of Urogynecology and Reconstructive Pelvic Surgery at Women & Infants and at The Warren Alpert Medical School of Brown University.

"There are more than 10 million women who suffer from incontinence in America today and more than 50,000 women in Rhode Island alone. That's about one in four between the ages of 30 and 59," said Dr. Myers. "For some women, medications and physical therapy may not help. If we can find another therapy option for these women, we can dramatically impact their quality of life. That's what studies like ROSETTA are all about."

The ROSETTA Study will compare the effect of two therapies in women who have bothersome urinary urge incontinence after trying other treatments. The two new treatments are:

  • Botox, a medication injected into the bladder, or
  • InterStim Therapy, a reversible treatment that uses mild electrical pulses to stimulate nerves going to the bladder (neuromodulation) that influence bladder function.

Women who may be eligible to participate are over 21 years of age, report symptoms of urge incontinence or overactive bladder, experience this leakage two or more times a day, and have tried other treatments including oral medication. Participation will include receiving one of the two procedures and monthly office visits or telephone follow-up for six months and follow-up every three to six months for 24 months.


'/>"/>

Contact: Amy Blustein
ablustein@wihri.org
401-681-2822
Women & Infants Hospital
Source:Eurekalert

Related medicine news :

1. Women decrease condom use during freshman year of college, study finds
2. Fewer women need repeat breast cancer surgeries with new service at University of Michigan
3. The North American Menopause Society (NAMS) reassures many women
4. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
5. Stem Cell Finding Could Expand Womens Lifetime Supply of Eggs
6. Contraceptives Work Well in Obese Women, But Hormone Levels Lower
7. Citrus Fruits May Lower Womens Stroke Risk
8. Mammograms Can Save Lives of Women in Their 40s: Study
9. Eating Fish May Help Ward Off Colon Polyps in Women
10. Women with rheumatoid arthritis and lupus give birth to fewer children
11. Circulatory Disorder Not Studied Enough in Women, Experts Say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: